Trial
NCT02516670
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
National Cancer Institute (NCI)
Condition
Hormone-Resistant Prostate Cancer
Intervention
Ascorbic Acid
Why stopped
insufficient clinical response per DSMB
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-07